A71623
Based on 1 Customer Validation
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.
For research use only. We do not sell to patients.
- Purity: 99.34%
- CAS No.: 130408-77-4
- Formula: C44H56N8O9
- Molecular Weight:840.96
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Biological Activity
|
CCKAR |
In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice[3].
A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male, Sprague-Dawley rats[2]
-
Dosage:5 μL
-
Administration:Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
-
Result:Reduced food intakes and suppressed intakes of a liquid diet.
-
Animal Model:ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice [3]
-
Dosage:0.02 mg/kg/day
-
Administration:Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
-
Result:Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice.
Improved motor performance in ATXN2[127Q] mice.
Chemical Information
-
CAS No. 130408-77-4
-
Appearance Solid
-
Molecular Weight 840.96
-
Formula C44H56N8O9
-
Color White to off-white
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvent & Solubility
DMSO : 50 mg/mL (59.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. C W Lin, et al. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39(3):346-51. [Content Brief]
[2]. K E Asin, et al. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. 1992 Jan 31;571(1):169-74. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1891 mL | 5.9456 mL | 11.8912 mL | 29.7279 mL |
| 5 mM | 0.2378 mL | 1.1891 mL | 2.3782 mL | 5.9456 mL | |
| 10 mM | 0.1189 mL | 0.5946 mL | 1.1891 mL | 2.9728 mL | |
| 15 mM | 0.0793 mL | 0.3964 mL | 0.7927 mL | 1.9819 mL | |
| 20 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4864 mL | |
| 25 mM | 0.0476 mL | 0.2378 mL | 0.4756 mL | 1.1891 mL | |
| 30 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.9909 mL | |
| 40 mM | 0.0297 mL | 0.1486 mL | 0.2973 mL | 0.7432 mL | |
| 50 mM | 0.0238 mL | 0.1189 mL | 0.2378 mL | 0.5946 mL |